Immunogenicity considerations for antibody–drug conjugates: a focus on neutralizing antibody assays

BioanalysisVol. 10, No. 2 CommentaryImmunogenicity considerations for antibody–drug conjugates: a focus on neutralizing antibody assaysCorinna K FiorottiCorinna K Fiorotti*Author for correspondence: Tel.: +857 540 9143; E-mail Address: corinna.fiorotti@bioagilytix.com BioAgilytix Labs, LLC, 2300 Englert Drive, Durham, NC 27713, USASearch for more papers by this authorPublished Online:15 Dec 2017https://doi.org/10.4155/bio-2017-0229AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleReferences1 Schwartz RS. Paul Ehrlich's magic bullets. N. Engl. J. Med. 350, 1079–1080 (2004).Crossref, Medline, CAS, Google Scholar2 Sievers EL, Senter PD. Antibody–drug conjugates in cancer therapy. Annu. Rev. Med. 64, 15–29 (2013).Crossref, Medline, CAS, Google Scholar3 Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br. J. Clin. Pharmacol. 76(2), 248–262 (2013).Crossref, Medline, CAS, Google Scholar4 Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 16(2), 209 (2014).Crossref, Medline, Google Scholar5 Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346(7), 469–475 (2002).Crossref, Medline, CAS, Google Scholar6 US FDA. Guidance for Industry. Immunogenicity Assessment for Therapeutic Protein Products. Washington, DC, USA (2014). www.fda.gov/downloads/drugs/guidances/ucm338856.pdf.Google Scholar7 US FDA. Draft Guideline. Guidance for Industry. Assay Development and Validation for Immunogenicity Testing of Therapeutic Protein Product. Washington, DC, USA (2016). www.fda.gov/downloads/Drugs/Guidances/UCM192750.pdf.Google Scholar8 Committee for Medicinal Products for Human Use. Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. European Medicines Agency, London, UK (2015). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/10/WC500194507.pdf.Google Scholar9 Koren E, Smith HW, Shores E et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 333(1–2), 1–9 (2008).Crossref, Medline, CAS, Google Scholar10 Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 25, 555–561 (2007).Crossref, Medline, CAS, Google Scholar11 Yin L, Chen X, Vicini P, Rup B, Hickling TP. Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products. Cell. Immunol. 295, 118–126 (2015).Crossref, Medline, CAS, Google Scholar12 Hollander I, Kunz A, Hamann PR. Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates. Bioconjug. Chem. 19(1), 358–361 (2008).Crossref, Medline, CAS, Google Scholar13 de Goeij B, Lambert JM. New developments for antibody-drug conjugate-based therapeutic approaches. Curr. Opin. Immunol. 40, 14–23 (2016).Crossref, Medline, CAS, Google Scholar14 Gorovits B, Krinos-Fiorotti C. Proposed mechanism of off-target toxicity for antibody–drug conjugates driven by mannose receptor uptake. Cancer Immunol. Immunother. 62(2), 217–223 (2013).Crossref, Medline, CAS, Google Scholar15 Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS. T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clin. Immunol. 149(3), 534–555 (2013).Crossref, Medline, CAS, Google Scholar16 Hock MB, Thudium KE, Carrasco-Triguero M, Schwabe NF. Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. AAPS J. 17(1), 35–43 (2015).Crossref, Medline, CAS, Google Scholar17 Carrasco-Triguero M. Insights on the immunogenicity of antibody–drug conjugates. Bioanalysis 7(13), 1565–1568 (2015).Link, CAS, Google Scholar18 Kadcyla (ado-trastuzumab emtansine) [prescribing information]. Genentech Inc., CA, USA (2016). www.gene.com/download/pdf/kadcyla_prescribing.pdf.Google Scholar19 Adcetris (brentuximab vedotin) [prescribing information]. Seattle Genetics, Inc., WA, USA (2016). www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_S056S078lbl.pdf.Google Scholar20 Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review: Adcetris. Office of Clinical Pharmacology, MD, USA (2011). www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125388Orig1s000ClinPharmR.pdf.Google Scholar21 Wyeth-Ayerst. Gemtuzumab ozogamicin, summary for presentation to the FDA's Oncologic Division Advisory Committee (2000). www.fda.gov/ohrms/dockets/ac/00/backgrd/3592b2c.pdf.Google Scholar22 Shankar G, Devanaryan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48(5), 1267–1281 (2008).Crossref, Medline, CAS, Google Scholar23 Mire-Sluis AR, Barrett YC, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289, 1–16 (2004).Crossref, Medline, CAS, Google Scholar24 Gorovits B, Wakshull E, Pillutla R, Xu Y, Manning MS, Goyal J. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics. J. Immunol. Methods 408, 1–12 (2014).Crossref, Medline, CAS, Google Scholar25 Hoofring SA, Lopez R, Hock MB et al. Immunogenicity testing strategy and bioanalytical assays for antibody–drug conjugates. Bioanalysis 5(9), 1041–1055 (2013).Link, CAS, Google Scholar26 Gupta S, Devanarayan V, Finco D et al. Recommendations for the validation of cell based assays used for detection of neutralizing antibody responses elicited to biological therapeutics. J. Pharm. Biomed. Anal. 55(5), 878–888 (2011).Crossref, Medline, CAS, Google Scholar27 Gupta S, Indelicato SR, Jethwa V et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Methods 321, 1–18 (2007).Crossref, Medline, CAS, Google Scholar28 Finco D, Baltrukonis D, Clements-Egan A et al. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics. J. Pharm. Biomed. Anal. 54(2), 251–358 (2011).Crossref, Google Scholar29 Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 9(10), 790–803 (2010).Crossref, Medline, CAS, Google Scholar30 Polakis P. Antibody drug conjugates for cancer therapy. Pharmacol. Rev. 68, 3–19 (2016).Crossref, Medline, CAS, Google Scholar31 Oflazoglu E, Stone IJ, Gordon KA et al. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood 110(13), 4370–4372 (2007).Crossref, Medline, CAS, Google Scholar32 Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res. Treat. 128(2), 347–356 (2011).Crossref, Medline, CAS, Google Scholar33 Committee for Medicinal Products for Human Use. Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for In vivo Clinical Use. European Medicines Agency, London, UK (2012). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf.Google Scholar34 Jolicoeur P, Tacey RL. Development and validation of cell-based assays for the detection of neutralizing antibodies to drug products: a practical approach. Bioanalysis 4(24), 2959–2970 (2012).Link, CAS, Google Scholar35 Wu B, Chung S, Jiang XR et al. Strategies to determine assay format for the assessment of neutralizing antibody responses to biotherapeutics. AAPS J. 18(6), 1335–1350 (2016).Crossref, Medline, CAS, Google Scholar36 Loebrich S, Shen M, Cohen E et al. Development and characterization of a neutralizing anti-idiotype antibody against Mirvetuximab for Analysis of Clinical Samples. AAPS J. 19(4), 1223–1234 (2017).Crossref, Medline, CAS, Google Scholar37 Li W, Lam MS, Birkeland A. Cell-based assays for profiling activity and safety properties of cancer drugs. J. Parmacol. Toxicol. Meth. 54, 313–319 (2006).Crossref, Medline, CAS, Google Scholar38 Barbosa MD, Gleason CR, Phillips KR et al. Addressing drug effects on cut point determination for an anti-drug antibody assay. J. Immunol. Methods 284(1–2), 152–156 (2012).Crossref, Google Scholar39 Chatterjee S, Vashishta L, Waichale VS et al. Development and validation of a cell based assay for the detection of neutralizing antibodies against recombinant insulins. J. Immunol. Methods 1759(17), 30153–30159 (2017).Google Scholar40 Ray CA, Patel V, Shih J et al. Application of multi-factorial design of experiments to successfully optimize immunoassays for robust measurements of therapeutic proteins. J. Pharm. Biomed. Anal. 49(2), 311–318 (2009).Crossref, Medline, CAS, Google Scholar41 Chen XC, Zhou L, Gupta S, Civoli F. Implementation of design of experiments (DOE) in the development and validation of a cell-based bioassay for the detection of anti-drug neutralizing antibodies in human serum. J. Immunol. Methods 376(1–2), 32–45 (2012).Crossref, Medline, CAS, Google Scholar42 Gorovits B, Clements-Egan A, Birchler M et al. Pre-existing antibody: biotherapeutic modality-based review. AAPS J. 18(2), 311–330 (2016).Crossref, Medline, CAS, Google Scholar43 O'Hara DM, Theobald V, Egan AC et al. Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents. AAPS J. 14(2), 316–328 (2012).Crossref, Medline, Google Scholar44 Geist BJ, Egan AC, Yang TY, Dong Y, Shankar G. Characterization of critical reagents in ligand-binding assays: enabling robust bioanalytical methods and lifecycle management. Bioanalysis 5(2), 227–244 (2013).Link, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByImplementation of Systematic Bioanalysis of Antibody–Drug Conjugates for Preclinical Pharmacokinetic Study of Ado-Trastuzumab Emtansine (T-DM1) in Rats24 February 2023 | Pharmaceutics, Vol. 15, No. 3Current Analytical Strategies for Antibody–Drug Conjugates in Biomatrices24 September 2022 | Molecules, Vol. 27, No. 19Bioanalytical methods for therapeutic monoclonal antibodies and antibody–drug conjugates: A review of recent advances and future perspectivesJournal of Pharmaceutical and Biomedical Analysis, Vol. 179Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody–Drug Conjugates21 August 2018 | BioDrugs, Vol. 32, No. 5 Vol. 10, No. 2 Follow us on social media for the latest updates Metrics Downloaded 423 times History Received 16 October 2017 Accepted 7 November 2017 Published online 15 December 2017 Published in print January 2018 Information© 2018 Future Science LtdFinancial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download